Additionally, it has been reported that AMPK activation decreases α-SMA -production in activated HSCs [36], suggesting that FGF21 could regulate AMPK phosphorylation to inhibit expression of α-SMA in a mouse model of NAFLD via triggering adiponectin release from adipocytes. Here, FGF21 is linked to metabolic dysfunction-associated steatotic liver disease.